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I.  INTRODUCTION 
¶1 Scientific research publications do not, as a rule, disclose the existence of patent 
rights associated with the subject matter of the publication.  Disclosure of patents and 
patent applications is typically required only when they constitute a competing financial 
interest that could bias authors in reporting their results and compromise their 
objectivity.1  However, there are other reasons to require patent disclosure in scientific 
literature. 
¶2 Scientific journal publications are one of the key channels through which scientists 
communicate and exchange information with each other.  The purpose of disseminating 
knowledge among scientists is to stimulate further research and discovery, as well as to 
promote practical applications of their work.  In furtherance of this goal, the scientific 
literature is generally considered to belong to the public domain, available to any scientist 
to read, implement, or improve upon.  The concept of scientific literature as a public 
resource is challenged when the technology it describes is the subject of a patent 
application.2  The publication literally puts the technology into the public’s possession, 
but the fact that a patent application has been filed manifests a clear intent to control its 
use.  When such restriction is not openly disclosed to the public, the publication contains 
a potentially deceptive message about the availability of the technology.  A patent 
application that is not disclosed in a scientific report, but later discovered by the public, 
may give the author the appearance of impropriety, even if no financial conflict exists.  
Thus, the failure to disclose patent rights can harm the integrity of the individual scientist, 
as well as the public image of the scientific community as a whole.   
¶3  A new duty to disclose patent rights is proposed here that would require the listing 
of all pertinent patents and patent applications in scientific publications.  Full disclosure 
promotes candor and truth telling, encouraging scientists to reveal all facts that could 
possibly have relevance to the objectivity of their work and the public image of the 
scientific community.  Finally, notice of patent rights also informs potential users of the 
technology that the authors intend to patent certain aspects of it, which may later restrict 
its use. 
 
* George Mason University Department of Environmental Science and Policy.  Correspondence address:  
313 Hillwood Avenue, Falls Church, VA 22046; Telephone: 703-328-6747; Email: biojuris@gmail.com.  
The author thanks Anthony Zelano and I. William Millen of Millen, White, Zelano, and Branigan for 
valuable contributions, including discussions, ideas, and editorial suggestions.  Professors Patrick Gillevet, 
Christopher Hill, and Steven Schiff are also thanked for insightful comments and suggestions. 
1 Philip Campbell, Declaration of Financial Interests, 412 NATURE 751 (2001). For information for 
authors listing patents and patents applications as an interest which might be a source of bias, see SCIENCE, 
Conflict-of-Interest Disclosure, http://www.sciencemag.org/about/authors/prep/coi.dtl (last visited Nov. 17, 
2007). 
2 Rebecca S. Eisenberg & Richard R. Nelson, Public vs. Proprietary Science: A Fruitful Tension?, 77 
ACAD. MED. 1392 (2002). 
 36 
Vol. 6:1] Richard M. Lebovitz 
¶4  Because many journals already require the disclosure of patent rights when they 
constitute a competing financial interest with the subject matter of the publication, we 
determined the extent to which patent rights are disclosed in the scientific literature and 
how effective the existing rules are in encouraging patent disclosure.3  Other studies have 
examined whether authors disclose patents as financial interests, but did not suggest an 
absolute ethical duty to disclose patent rights in the absence of competing financial 
interests.  4
II.  METHODS 
¶5 Research articles were surveyed from two leading journals, Nature and Science.  
Only research articles related to biomedical research were selected.5  Both journals had 
conflict-of-interest disclosure requirements.6  Nature specifically identified patent 
applications as a potential conflict, but Science did not (although the policy has 
subsequently changed).  7
¶6 All author names were searched in a freely available patent database maintained by 
the European Patent Office for applications that related to the research described in the 
article.8  The patent database contains published worldwide patents and patent 
applications, including published European, United States, and Patent Cooperation Treaty 
(PCT) applications.9  Since it can take as long as 18 months from the time of filing for a 
patent application to be published, the analysis was performed retrospectively on research 
articles which had been in the public domain for at least 30 months (selected from the 
period of January 2002-June 2002) to account for any errors or delays in the patent 
publication.  United States applications have been published since March 15, 2001 (for 
those filed after November 29, 2000);10 so if an application was only filed in the United 
States, it should have been detected by the search methods utilized here, unless the 
applicant specifically requested non-publication.   11
 
3 Scientific journals may require authors to declare competing financial interests that could bias an 
author’s judgment and objectivity in reporting his results.  Personal interest in patents and patent 
applications is considered a competing financial interest because its value may be affected by publication.  
4 Sheldon Krimsky et al., Financial Interests of Authors in Scientific Journals: A Pilot Study of 14 
Publications, 2 SCI. ENGINEERING ETHICS 395 (1996); see also S. Mayer, Declaration of Patent 
Applications as Financial Interests: A Survey of Practice Among Authors of Papers on Molecular Biology 
in Nature, 32 J. MED. ETHICS 658 (2006). 
5 Publications relating to ecology, evolution, neuropsychology, and psychology were not considered in 
this analysis.  However, all other biomedical and biological science-related publications were considered, 
including publications related to bioengineering. 
6 See http://www.nature.com/authors/editorial_policies/competing.html for NATURE (last visited Oct. 26, 
2007) and http://sciencemag.org/feature/contribinfo/prep/coi.dtl for SCIENCE conflict-of-interest disclosures 
(last visited Oct. 26, 2007). 
7 Since 2004, SCIENCE has asked authors specifically about patents in their conflict-of-interest policy 
(personal communication from SCIENCE editorial staff). 
8 Esp@cenet Portal, http://www.espacenet.com (last visited Oct. 26, 2007). 
9 See Patent Cooperation Treaty art. 8, 11, 62, June 19, 1970. 
10 Patent Full-Text and Full-Page Image Databases, http://www.uspto.gov/patft/index.html (last visited 
Oct. 26, 2007). 
11 In the United States, a patent applicant can request non-publication of her application to preserve its 
secrecy only if such request is made on the day the application is filed and if no other corresponding 
application has or will be filed in another country.  37 C.F.R. § 1.213 (2000). 
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¶7 Patent applications having claims to the main experimental subject matter 
described in the publication were scored as positive.  The results are listed in Table 1.  In 
all of these cases, working examples, figures, and data from the publication could be 
clearly identified in the corresponding patent application.  Patent applications which 
described materials or technology that would be needed to conduct the research described 
in the article were also identified in the searches.  These are referred to as “enabling 
technologies” because they are not the direct subject of the article, but are necessary to 
carry out the experiments described in the article.12  This category is listed in Table 1.  A 
material or technology was only counted as an enabling technology if there was at least 
one author of the journal article in common with the inventors listed on the patent or 
patent application. 
III.  RESULTS AND DISCUSSION 
¶8 The results of this study are summarized in Table 1.  Almost one-third (32.7 
percent) of the biomedical research articles surveyed in this study were associated with 
underlying patent applications.  Of all the applications, 17.9 percent directly covered the 
research disclosed in the scientific publication, and 11.7 percent were related to an 
enabling technology that was utilized in conducting the research.  In 3.1 percent of the 
cases, the authors filed for patent protection, but only after the publication had been 
published.  Despite the high number of patent applications associated with journal 
articles, disclosure was very low; 87.5 percent of patent rights were not disclosed to the 
public.  In another study, Mayer found two-thirds of the publications surveyed did not 
disclose patent applications or company affiliations.  13
¶9 Of the publications, 17.9 percent contained subject matter that was a direct topic of 
the application.  This number is comparable to the 22 percent value identified earlier by 
Krimsky et al., whose data was collected from 1992, 10 years before this study period.14  
While there was not a considerable difference (about 18 percent versus 22 percent) in 
publications associated with patent application filings from the previous decade, this 
current study was not designed to evaluate this issue, and the sampling methods differed 
between the two studies. 
¶10 Of the scientific publications, 11.7 percent did not disclose patent applications that 
related to an enabling technology, a category not identified by Krimsky.  This category is 
defined as technology that was not the primary subject of the publication, but which was 
necessary to perform the research reported in it and for which a patent application was 
filed by at least one co-author of the journal article.  For example, several publications 
described experiments in which genes or transgenic animals were utilized that were 
themselves the subject of undisclosed patents or patent applications filed previously by at 
least one coauthor of the publication.  If these experiments established a significant new 
utility for the patented or patent pending application, the publication would increase the 
 
12 Examples of enabling technology included proteins, genes, transgenic animals, purification 
procedures, and compounds which were used in the research article. 
13 Mayer, supra note 4, at 658. 
14 Krimsky, supra note 4, at 395.  Krimsky examined university authors from Massachusetts institutions 
who appeared in 14 scientific and medical journals.  In contrast, this study compiled data from two journals 
during a specific period of time, without consideration of the authors’ affiliations or geographic locations. 
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value of the previously filed patent, creating a clear financial conflict of interest.  It does 
not appear that journal policies have adequately addressed this type of financial conflict. 
¶11 With about one-third of the articles associated with patent rights, these results show 
the close intertwining of private intellectual property interests with published scientific 
literature.  The high frequency of this intertwining is not unexpected.  In the United 
States, federal policy under the Bayh-Dole Act of 1980 has encouraged academic 
institutions to commercialize discoveries made with federal funds.15  Patents are a strong 
component of the commercialization process.  They enable the patent owner to restrict 
competitors from copying patented products, to carve a niche in the marketplace, and to 
use the patent as a source of revenue through patent licensing.  In 2004, there were two 
academic institutions in the top 15 holders of U.S. deoxyribonucleic acid patents.  16
TABLE 1. 
SCIENCE NATURE TOTAL  
Percent Percent Percent Number Number Number 
Total number of publications 81  81  162  
1. Patent application discloses 
research in article 17.3 18.5 17.9 14 15 29 
2. Patent applications on related 
and earlier technology 
(“enabling technology”) 
11.1 12.3 11.7 9 10 19 
Total of patent applications related to 
research article and filed prior to 
publication 
28.4 30.9 29.6 23 25 48 
3. Patent applications filed after 
publication 2.5 3.7 3.1 2 3 5 
30.9 34.6 32.7 Total of all application categories 25 28 53 
4.3 20.0 12.5 1 5 6 Application is disclosed in article   (1/23)  (5/25)  
  87.5 Patent non-disclosure 22 20 42 
At least one author in the research 
group is listed as an inventor of a 
patent or patent application 
76.5 82.7 79.6 62 67 129 
¶12 In addition to the findings about patent stakes in the particular articles reviewed, a 
search was conducted of all article authors to determine whether they were listed as an 
inventor of any patent or patent application.  For the purpose of this analysis, all the 
authors of a single article are referred to as a “research group.”  The results presented 
here show a high proportion (79.6 percent) of research groups (Table 1) with at least one 
member who also files patent applications, suggest the success of the Bayh-Dole Act in 
promoting commercialization of government-funded research.  17
 
15 35 U.S.C. § 200 (2000). 
16 David Malakoff, NIH Roils Academe with Advice on Licensing DNA Patents, SCIENCE., Mar. 19, 
2004, at 1757 (identifying the University of California and The Johns Hopkins University).  
17 Presently, there is no universal rule in the European Community (EC) about patent ownership, 
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¶13 Although a high number of scientists pursue patent protection for their scientific 
work, this is not transparent to the scientific community in the journals in which they 
publish.  In Science, for the period of time surveyed, where patent applications were not 
expressly described as a potential conflict-of-interest, no authors disclosed that their 
publication was the subject of a patent application.  On the other hand, in Nature, where 
patent applications were listed as a possible financial conflict of interest, some authors 
did disclose their patent filing, but the number was low, with only 20 percent (5 of 25) 
disclosing the existence of a filed patent application.  In total from both journals, only 
12.5 percent of patent rights were disclosed to the public. 
¶14 This low frequency leads to several conclusions.  First, scientists do not perceive 
the existence of patent rights as requiring disclosure.  Secondly, patents are not 
considered by scientists as a per se financial conflict of interest.  Thus, financial 
disclosure rules are insufficient to ensure complete patent disclosure in the scientific 
literature.   
¶15  The rare disclosure of a patent application when there is no perceived financial 
interest indicates that scientists, on their own, do not recognize any duty to disclose 
patent rights to the public.  This fact is not surprising.  The three major patent systems — 
in the United States, Europe, and Japan — each have a period during which patent 
applications are kept secret.  Europe and Japan publish patent applications 18 months 
after filing, giving patent applicants a limited period during which their application is 
shielded from discovery.  The U.S. adopted this pre-grant publication period in 2000, but 
before this time, applications were kept secret until the patent was granted by the Patent 
Office.  Consequently, the patent system does not encourage disclosure of applications, 
but protects their secrecy.   
¶16  Despite the patent’s system strong commitment to a limited period of secrecy, 
should this secrecy be protected when patent applications are the subject of a scientific 
publication?  Conflict-of-interest rules utilized by at least some scientific journals require 
that the secrecy be waived when there is a financial conflict of interest.  The results of 
this study indicate that these rules elicit disclosure of only 20 percent of journal 
publications associated with patent rights. 
A.  Should There Be a Duty to Disclose Patent Applications, 
apart from Competing Financial Interest Rules? 
¶17 The juxtaposition of patents and scientific literature creates an inherent conflict 
between the public nature of scientific literature and the proprietary rights of patents.  
Patents are primarily for the purpose of controlling the use of a technology, while the 
function of scientific literature is to fully disclose the technology and make it freely 
available to the public.  When a patent is granted, the patented subject matter cannot be 
practiced freely without a license from the patent owner.  In contrast, the unfettered 
practice of a technology described in a journal publication is important for others to 
validate and build on the scientific work.  Thus, the act of patenting and publishing 
 
although several European countries have adopted intellectual property provisions that mirror the Bayh-
Dole Act, and it has been suggested that the EC as a whole enact similar legislation. See EC, Management 
of Intellectual Property in Publicly-Funded Search Organizations: Towards European Guidelines (Expert 
group report, Working Paper EUR 20915 EN, 2004), available at 
http://europa.eu.int/comm/research/era/pdf/iprmanagementguidelines-report.pdf. 
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creates a conflict of purpose.  As explained in more detail below, when the conflict of 
purpose is not disclosed, there are harmful consequences to the scientific process and 
community. 
B.  Harm to Integrity 
¶18 The failure to disclose the existence of patent rights in a journal publication can 
give the appearance of impropriety when the rights later become discovered.  In a journal 
that requires disclosure of competing financial interests, it can raise suspicion that there is 
a financial interest at stake and that the author intentionally decided not to disclose it.  
The author may have determined that the value of the patent rights would be unaffected 
by publication, and therefore, did not constitute a competing financial interest.  However, 
while this determination may be perfectly valid at the time, it may not be perceived so by 
the public.  This is detrimental to not only the scientist’s reputation, but it could also 
suggest to the public that the work is tainted or biased, when it is not. 
¶19 Moreover, even when there is no actual competing financial interest necessitating 
disclosure of a patent application, non-disclosure — when it becomes known to the 
public — can lead to public mistrust of the scientific community.  The Canavan dispute is 
a good example of this.  In 1997, a patients’ advocacy group for Canavan disease 
discovered that scientists, with whom they had been cooperating by providing patient 
samples, had filed and obtained a patent on the disease gene and a diagnostic test for it, 
although at no time — either to the patient group or in journal articles reporting the 
gene’s discovery — had this been disclosed.18  A lawsuit was brought on behalf of 
children afflicted with the disease in which it was alleged that the scientists intentionally 
concealed their plan to patent the disease gene in order to reap all financial benefit for 
themselves.19  The case eventually settled, but not without acrimony between the 
scientific community and patient advocacy groups.20  With publicity of this kind, 
scientists as a community have had to contend with mistrust and lack of confidence in the 
scientific community.  
¶20 A failure to disclose patent rights can also reflect a scientist’s desire to distance 
himself from commercial applications for fear that either he or the work will be taken less 
seriously.  This is disingenuous.  Scientific research furthers our understanding of the 
world and how it works, but also, when translated into commercial products, has the 
potential to transform and improve lives.  Viewing science as either a quest for 
knowledge for knowledge’s sake or a commercial endeavor aimed at making money, is a 
false dichotomy when a single discovery can satisfy both aims.  The Bayh-Dole Act 
recognizes this duality — encouraging commercialization of the applied aspects of the 
research, while the scientists continue to pursue their independent research goals. 
 
18 Rajinder Kaul et al., Cloning of the Human Aspartoacylase cDNA and a Common Missense Mutation 
in Canavan Disease, 5 NATURE GENETICS 118 (1993); U.S. Patent No. 5,679,635 (filed Sept. 9, 1994).  
19 Greenburg v. Miami Children’s Hosp. Res. Inst., Inc., 264 F.Supp.2d 1064 (S.D.Fla. 2003). 
20 Canavan Foundation, Gene Patent Lawsuit May Radically Affect Research, 
http://www.canavanfoundation.org/news/09-03_miami.php (last visited Nov. 28, 2007). 
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C.  Harm to Objectivity 
¶21 Even when patent rights have no personal financial value that would require their 
declaration in a journal article, they may still compromise the perceived or true 
objectivity of the publication, one of the driving forces behind the conflict-of-interest 
guidelines.21  Companies that sponsor research may review employee and grantee 
manuscripts prior to editorial submission and publication to cleanse them of statements 
that could be construed as inconsistent with a patent position or that could adversely 
affect future patent filings.  For example, the author may be a salaried employee and not 
consider himself to have any financial interest in the patent application, but in “clearing” 
the publication with the company’s patent counsel, the counsel may insist on substantive 
changes that he believes would impact the company’s patent position.  In such cases, the 
publication content may not be a neutral reflection of the data, but may be shaped by 
considerations outside the scope of its scientific purpose. 
D.  Harm to Data Sharing 
¶22 This conflict of purpose between patenting and publishing in the scientific literature 
has serious consequences for data sharing in the scientific community.  Patents have been 
characterized as a means to protect the commercial potential of scientific discoveries 
while continuing to disseminate the results of the research.22  However, patents — by 
requiring a license to practice the patented subject matter — have the potential to block 
the use of materials utilized in the research findings, hampering the goal of data and 
material sharing.  
¶23 There has been continued emphasis on procedures ensuring that information is 
shared among scientists.  After publication, scientific journals may require that data and 
research materials be shared upon request.  Nature requires as a condition of publication 
that authors “make materials, data and associated protocols available . . . to readers 
promptly on request.”23  Deoxyribonucleic acid sequencing projects have given the same 
attention to public access to gene sequencing information.  In guidelines published by the 
first International Strategy Meeting on Human Genome Sequencing, participants issued a 
statement that “all genomic sequence information should be ‘freely available and in the 
public domain in order to encourage research and development and to maximize its 
benefit to society.’”  24
¶24 United States funding agencies have also placed an emphasis on making research 
results freely accessible to the public.  Beginning May 2, 2005, the National Institutes of 
Health (NIH) has requested that NIH-funded investigators provide electronic copies of 
final manuscripts to the NIH Library of Medicine for archiving purposes.  This policy is 
 
21 See Krimsky, supra note 4, at 397; Frank Davidoff et al., Sponsorship, Authorship, and 
Accountability, 345 NEW ENG. J. MED. 825, 826-27 (2001). 
22 Committee on the Conduct of Science, National Academy of Sciences of the U.S.A., On Being a 
Scientist,  86 PROC. NAT’L ACAD. SCI. 9053 (1989), available at 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=2594750. 
23 See  Nature, Availability of Data and Materials, 
http://www.nature.com/authors/editorial_policies/availability.html (last visited Nov. 30, 2007). 
24 David R. Bentley, Genomic Sequence Information Should Be Released Immediately and Freely in the 
Public Domain, SCIENCE, Oct. 25, 1996, at 533 (quoting from The Bermuda Statement, 7 Human Genome 
News 19 (1996)). 
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to ensure that research results and accomplishments of NIH-funded investigators are 
freely “available to the research community and public at large.”  25
¶25 Because patent rights can undermine these data-sharing goals, scientists should 
have an independent duty to put the public on notice that the content of a published 
article is associated with patent rights that have the potential to restrict the free sharing of 
materials. 
E.  Misrepresentation 
¶26  When a new technology is described in a scientific journal, its authors will often 
boast about it, describing its advantages over pre-existing technology.  One evident 
reason for these statements may be self-serving, to convince the reviewers and readers 
that the technology is good and merited publication.  But a scientific publication that 
describes the advantages of a new technology may intentionally be doing more than 
merely exercising its deserved bragging rights; it may be persuading other scientists to 
use the technology in their own research programs.  For academia, this is within the 
intended purpose of scientific publications: to trade ideas and discoveries freely with 
other scientists in order to advance knowledge.  But, when the scientists and their 
institutions have filed patent applications on the technology, the intent becomes less 
clear.  Once a patent application matures into a granted patent, the owners of it have the 
right to exclude all others from using the patented technology.  The scientific publication 
assumes a dual purpose: to disseminate information, but also to promote the technology 
to potential licensees.  Not putting the public on notice that the technology is the subject 
of patent rights risks misrepresenting the inventors’ intent to control the practice of the 
invention and potentially elicits reliance on the fact that it is free to use, when it may not 
remain so. 
¶27  With almost 80 percent of the journal articles having at least one author who has 
filed a patent application, it is clear that the scientific community is familiar with the 
patent system.  Consequently, although there is a potential for a party to detrimentally 
rely on the free availability of a technology in a published journal article, when it may not 
remain so, it can be assumed that most parties are aware that a published technology may 
also be pending patent.  Nonetheless, because patent applications are published 18 
months after filing, there is at least an 18-month gap before even the most diligent party 
can determine the existence of a patent application.  This leaves a period of time where 
the technology is apparently in the public domain, but with no “user beware” sign to warn 
of inchoate patent rights. 
F.  Inadequacy of Financial Conflict Rule 
¶28 Disclosure of financial conflict-of-interest is an obvious necessity to avoid bias and 
compromising objectivity when conducting scientific research.  It is a mistake to leave it 
to the authors to decide for themselves whether the patent or patent application is a 
financial interest that requires disclosure.  First, an unintentionally wrong decision 
defeats the purpose of the rule: a financial interest that could bias the author’s published 
 
25 Policy on Enhancing Public Access to Archived Publications Resulting from NIH-Funded Research, 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-022.html (last visited Oct. 26, 2007). 
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results is left unreported.  Secondly, there are no clear rules on when a patent right is a 
competing financial interest.  For example, is an unlicensed patent application, which is 
filed on the same day that a manuscript is submitted to a journal, a financial conflict of 
interest when the author is an employee of a major pharmaceutical company who owns 
none of the company stock?  Is the situation different if the author is an academic who, 
through university patent policy, receives 50 percent of the licensing income from the 
patent application?  These ambiguities leave a loophole in the rule, opening the door for 
rule-bending.  An author who may want to keep the application secret can use the 
imprecision built into the rule to justify non-disclosure.  
¶29 Disclosure rules need to go deeper than the typical financial conflict of interest 
rules to ensure that scientific research is conducted in an atmosphere of full disclosure.  
Patent rights should not be excluded from this realm of openness.  A patent right is a 
finger of the private sector in the public information cookie jar, and the scientist has the 
social duty to let the public know.  Science and technology have important societal 
ramifications — for example, in genetic engineering, cloning, stem cell technology, and 
new drug development.  Full disclosure allows the public to police the scientific 
community and engage in meaningful dialogues about the relationship between science, 
commerce, and ethics. 
G.  Is the Public Harm Significant Enough to Sacrifice the Secrecy Period? 
¶30 A pertinent consideration in adopting a universal disclosure rule is whether there is 
any harm to patent owners.  The patent system gives inventors a period of exclusivity in 
which to use their inventions in return for publicly disclosing how to make and use the 
invention.26  This encourages inventors to share their results with the public rather than 
keeping them a trade secret.  The exclusivity period has two forms.  First, once a patent is 
granted on an invention, the owners have a period in which they can exclude others from 
practicing the invention.  Thus, although the inventor is required to fully describe how to 
make and use his invention to the public, the fact is that it cannot be practiced without a 
license to the patent.  Second, the application has a period in which its content and 
existence is kept secret.  Europe and Japan have long published applications 
automatically 18 months after the filing date.  The United States has only recently 
adopted this practice.  The 18-month pre-grant publication rule gives inventors a limited 
period in which to keep all details of the application in confidence, avoiding tipping off 
competitors and giving inventors a leading edge.  However, once the application is 
published, the veil is lifted.  Requiring scientists to disclose the existence of a patent in a 
publication clearly could impact the length of the limited period during which the 
application is kept secret.   
¶31  Intellectual property rights are not harmed by disclosure of the existence of a 
patent application in the first publication of the technology.  Once a patent application 
has been filed, the inventors have secured their patent rights as of the day of filing and 
subsequent disclosure, even of the entire application content, does not injure these 
inchoate rights.  The requirement that a patent application be disclosed to the public has 
the potential to infringe upon the 18-month publication rule that gives inventors a limited 
period of secrecy during which they can develop and exploit their invention without the 
 
26 35 U.S.C. §§ 112, 154 (2000). 
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knowledge of competitors.  However, by making their invention public in a scientific 
journal, the inventors have already surrendered this period of secret exclusivity.  
 Moreover, the application itself is confidential, so any information and technology 
not disclosed in the publication can be kept from public view.  Unless complete 
transparency required authors to provide copies of the patent application, they would still 
retain control over its dissemination.  Accordingly, a universal patent disclosure rule 
should not deter inventors from publishing their work. 
¶32  What does full disclosure require?  The minimum is to inform the reader that a 
patent application has been filed on subject matter described in the publication, or the 
intent to do so.27  This puts the reader on notice that the technology described in the 
article is not being placed in the public domain, but that certain rights are being reserved 
in it.  In addition to knowing the existence of the application, a reader might also want to 
know details of the filing, such as application type and country of filing, the application 
contents, whether the technology is available for licensing, and even the technology 
licensing terms.  However, if the point is to make the reader aware that intellectual 
property rights have been retained, then to satisfy this requirement it should only be 
necessary to tell the public that an application has been filed and to provide a point of 
contact where further inquiries can be made.  Contact information seems reasonable to 
facilitate further inquiry about the application status. 
 
27 In most countries, except the U.S., a prior publication by the inventors is a bar to patentability.  35 
U.S.C. § 102(a) (2000).  To protect worldwide patent rights, a patent application is generally filed before 
publication.  However, in circumstances where the authors publish prior to filing, they should disclose their 
intent to file a patent application. 
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